Abstract
Matrix metalloproteinase-9 (MMP-9) is abundantly expressed in abdominal aortic aneurysms (AAAs), and it is considered to play a pivotal role in aneurysmal formation. Elevated circulating concentrations of MMP-9 have been reported in patients with AAA, but the influence of an operation on circulating MMP-9 is unclear. Therefore, to clarify the influence of an operation on circulating MMP-9 levels and to determine the role of MMP-9 in the progression of AAA, we measured serum MMP-9 levels in patients before and after AAA repair. Blood samples were obtained from 53 patients with AAA; 22 patients underwent AAA operations, including 17 patients with arterial occlusive disease (AOD), and nine normal control subjects. Serum MMP-9 levels were determined by an enzyme-linked immunosorbent assay. The serum MMP-9 concentration was significantly higher in AAA patients (622.0 ± 400.2 ng/mL) than in either AOD patients (284.3 ± 151.4 ng/mL) or healthy controls (280.8 ± 165.5 ng/mL) (p < 0.001). The mean serum MMP-9 levels in patients undergoing surgery for AAA (268.1 ± 215.9 ng/mL) was significantly lower than that in AAA patients (p < 0.01). Among the 10 patients whose sera were obtained preoperatively and postoperatively, the serum MMP-9 concentration fell significantly after the patients underwent the operation (p = 0.004). No significant difference was identified in serum MMP-9 concentrations among AOD patients, controls, and postoperative patients. These studies suggest that MMP-9 plays a pivotal role in aneurysm formation, and the circulating MMP-9 level is thus considered to reflect the biological behavior of the aneurysm.
Similar content being viewed by others
References
Ailawadi G, Eliason JL, Upchurch GR Jr. Current concepts in the pathogenesis of abdominal aortic aneurysm. J Vasc Surg 2003;38:584–588
Rizzo RJ, McCarthy WJ, Dixit SN, et al. Collagen types and matrix protein content in human abdominal aortic aneurysms. J Vasc Surg 1989;10:365–373
Baxter BT, Halloran BG. Matrix protein metabolism in abdominal aortic aneurysms In: Yao JST, Pearce WH eds. Aneurysms. New Findings and Treatments. Nortwalk: Appleton & Lange, 1994, pp 25–34
Carrell TWG, Burnand KG, Wells GMA, et al. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2001;105:477–482
Newman KM, Malon AM, Shin RD, et al. Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res 1994;30:265–276
Knox JB, Sukhova GK, Whittemore AD, et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997;95:205–212
McMillan WD, Patterson BK, Keen RR, et al. In situ localization and quantification of seventy-two-killodalton type IV collagenase in aneurysmal, occlusive and normal aorta. J Vasc Surg 1995;22:295–305
Freestone T, Turner RJ, Coady A, et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Atheroscler Thromb Vasc Biol 1995;15:1145–1151
Sakalihansan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005;365:1577–1589
Thompson RW, Holmes DR, Mertens RA, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995;96:318–326
Sakalihasan N, Delvenne P, Nusgens BV, et al. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 1996;24:127–133
Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625–632
Watanabe T, Sawai T, Sato A, et al. The role of matrix metalloproteinases in progression of abdominal aortic aneurysm. J Jpn Coll Angiol 2000;40:505–510
Watanabe T, Sawai T, Sato A, et al. Mapping analysis of the distribution of MMP-2 and MMP-9 in the wall of abdominal aortic aneurysms and correlation with the disruption of elastic fibers. Jpn J Vasc Surg 2000;9:539–544
Tilson MD, Newman KM. Proteolytic mechanisms in the pathogenesis of aortic aneurysms. In: Yao JST, Pearce WH eds. Aneurysms. New Findings and Treatments. Norwalk: Appleton & Lange, 1994, pp 3–10
Hovsepian DM, Ziporin SJ, Sakurai MK, et al. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000;11:1345–1352
McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999;29:122–129
Lindholt JS, Vammen S, Fasting H, et al. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg 2000;20:281–285
Seki M, Uzuki M, Ohmoto H, et al. Matrix metalloproteinase (MMP-9) in patients with rheumatoid arthritis. Ryumachi 1995;35:792–801
Hibbs MS. Expression of 92kDa phagocyte gelatinase by inflammatory and connective tissue cells. Matrix 1992;(Suppl. 1):51–57
Acknowledgement
The authors thank Kanebo Corporation (Osaka, Japan) for their generous contribution of the reagents for the MMP-9 assay.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Watanabe, T., Sato, A., Sawai, T. et al. The Elevated Level of Circulating Matrix Metalloproteinase-9 in Patients with Abdominal Aortic Aneurysms Decreased to Levels Equal to Those of Healthy Controls after an Aortic Repair. Ann Vasc Surg 20, 317–321 (2006). https://doi.org/10.1007/s10016-006-9038-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10016-006-9038-7